liraglutide, Victoza (cont.)

Pharmacy Author:
Medical and Pharmacy Editor:

Combining liraglutide with insulin or drugs that stimulate release of insulin (for example, glyburide) may increase the occurrence of low blood sugar (hypoglycemia). The dose of insulin or the insulin release stimulating drug should be reduced.

There have been reports of acute pancreatitis associated with the use of liraglutide. Patients developing severe, persistent abdominal pain that might be caused by pancreatitis, should seek prompt medical attention. If pancreatitis is suspected, liraglutide should be discontinued and not started again until the presence of pancreatitis has been excluded.

Liraglutide can cause thyroid tumors that occur more frequently at higher doses and with longer duration of treatment. Since liraglutide is a synthetic protein patients may develop antibodies to liraglutide. Liraglutide antibodies may reduce the effectiveness of liraglutide.

REFERENCE: Reference: FDA Prescribing Information

Last Editorial Review: 2/17/2012 2:28:20 PM

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.

Back to Medications Index